SenoRx, producer of medical devices for the diagnosis and treatment of breast cancer, lowered the range of its IPO Wednesday. The company will offer their shares at an anticipated price range of $9.00 to $10.00, 21% below the midpoint of the originally announced range of $11.00 to $13.00. The number of shares offered remains at 5.5 million, and the stock is still expected to begin trading on Thursday. Banc of America and Citigroup are the bookrunners on the deal.
